Speaker: Jonathan Strosberg
Date: December 14, 2017 at 3:00pm ET
SNMMI Member Fee: $49 | Nonmember Fee: $79
Join Dr. Jonathan Strosberg from the H. Lee Moffitt Cancer Center for the one-hour webinar: 177-Lutetium Dotatate - Incorporating it in Your Clinic.
In this webinar, Dr. Strosberg will summarize the development of peptide receptor radiotherapy for neuroendocrine tumors with a particular focus on 177-Lutetium Dotatate (Lutathera). The potential role of 177-Lutetium Dotatate within the therapeutic landscape of NETs will be discussed.
About the Presenter:
Dr. Jonathan Strosberg is an associate professor at the H. Lee Moffitt Cancer Center, specializing in management of gastrointestinal and neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College, and completed his residency and fellowship training programs at Georgetown University Hospital and H. Lee Moffitt Cancer Center. He leads the neuroendocrine tumor division at Moffitt and heads the gastrointestinal department research program. He also serves as chair of the scientific review committee.
Dr. Strosberg has published over one hundred articles on the diagnosis and management of neuroendocrine malignancies in the New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Cancer, and other major journals, and has written twelve articles for UptoDate. He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award. He serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), on the neuroendocrine guidelines committee of the National Comprehensive Cancer Network (NCCN), and on the neuroendocrine task force of the National Cancer Institute (NCI) and the neuroendocrine staging committee of the American Joint Committee on Cancer (AJCC).